REVIEW ON ANTIMALARIAL DRUGS

Pharmacy

The primary reason for the sharp rise in recent years in the search and development of novel antimalarial medications has been drug resistance to those already in use. Data from a variety of preclinical test systems are taken into account when choosing potential medications for human clinical trials and when developing clinical protocols. Every chemical is first evaluated using one or more primary screening models. A substance that passes the first screening test with well- defined criteria as "active" is evaluated further in a series of subsequent clinical tests. Upon completion of every testing phase, a determination is made regarding whether to proceed with the chemical to the subsequent phase or end it. Primary screening tests ought to be low-cost, require a minimal amount of test substance, have a high degree of repeatability, high throughput, and excellent sensitivity. More sensitive and affordable screening models are required, as the need for newer and more effective antimalarial medications, particularly in tropical nations, is expanding. This review provides an update on the many traditional and cutting-edge in vitro and in vivo screening techniques used to assess antimalarial drugs.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.